How Sustainable Packaging Is Influencing Pharmaceutical Manufacturing Decisions

Sustainable Packaging Has Reached the Plant Floor

For years, sustainable packaging was a topic for annual reports, usually illustrated by a lighter carton or a recycled shipper. That separation is breaking down. In the United States, state packaging laws now carry fees and penalties, large health systems are writing climate goals into supplier contracts, and investors and boards are asking about value chain emissions.

None of this overrides the first duty of a drug package, which is to protect the medicine and the patient. It does mean that packaging choices made late in development can now lock in cost, regulatory work and environmental exposure for the life of a product. For US pharmaceutical executives, the useful question is no longer whether packaging is sustainable enough. It is which manufacturing decisions should change because of it, and when.

Fifty States, No Single Rulebook: Sustainable Packaging Law Meets US Pharma

With no federal packaging statute to work from, the pressure is arriving state by state. Seven states have enacted packaging extended producer responsibility laws: Maine, Oregon, Colorado, California, Minnesota, Maryland and Washington. California's regulations took effect on May 1, 2026, with full program implementation due in January 2027. By 2032 the law targets a 25% reduction in plastic covered material, a 65% recycling rate for plastic and fully recyclable or compostable covered material. Penalties can reach $50,000 per day per violation.

Many drug makers assume these laws do not apply to them, and that assumption deserves testing. Most state laws do carve out medical or federally regulated packaging, but the wording varies, and one published comparison lists Maine as the exception on medical packaging. California's rules separate exclusions, which remove material from the program, from exemptions, which still leave fee and reporting obligations in place. Whether a given primary pack, carton, insert or shipper falls inside a carve-out, and whether over-the-counter lines are treated like prescription products, is a question for counsel to settle product by product.

The legal ground is also moving. As of mid-2026, Oregon's law faced an injunction limited to members of one trade association, while California's faced both an environmental challenge and a federal suit backed by 17 state attorneys general. Attorneys tracking these cases caution that pending litigation does not by itself justify delay, so a reasonable planning stance is to prepare the data now while keeping major capital commitments flexible.

The Customer in the Contract: Why Hospital Buyers Now Care About Pharma Packaging

Regulation is only one route by which sustainable packaging reaches the factory. The other runs through customers and climate commitments. One of the largest US integrated health systems has been adding decarbonization goals to its supplier contracts, and it set a target for half of its supply spend to go to suppliers with matching commitments.

Manufacturers feel the arithmetic themselves. One global injectable maker reports that 96% of its emissions sit in Scope 3, largely outside its direct control. Packaging is among the few parts of that footprint a manufacturer can redesign directly, which is why it attracts board attention beyond its share of emissions. Sustainable packaging also has a commercial logic that survives any shift in political climate. A large US drug maker reported in 2020 that redesigning a single package insert saved 70 tons of paper a year, cut ocean container needs by 30% and saved more than $2 million annually.

Barrier Versus Recyclability: The Sustainable Packaging Trade-Off Inside the Plant

The clearest manufacturing example is the blister pack, the preferred format for oral solids for about half a century. Conventional PVC and aluminum constructions protect well but are difficult to recycle. Mono-material polypropylene alternatives now exist. One supplier cites a life cycle assessment showing up to 47% lower climate impact than PVC/PVdC and aluminum packs, and states that its film runs on many existing PVC lines without modification. These are vendor figures and should be tested.

Industry working groups paint a more demanding picture. Fully polymeric packs may struggle to match the barrier of existing structures. New materials can require reshaped forming cavities, low-friction coatings, pre-heating or plug assist, and thin films can soften during machine stops, which makes high line speeds harder to sustain. Materials not yet established in pharmaceutical use may need extractables and leachables work. Recyclability itself also depends on inks, adhesives and additives, and on what actually happens after disposal. Polypropylene recycling is mature in Europe, whereas US collection of that resin has been described as still developing, so a recycle-ready pack does not guarantee a recycled one.

Lower carbon and better recyclability do not always travel together either. Working group analysis suggests that removing aluminum lidding can cut CO2 equivalents by at least 50%, and that moving from large aluminum-aluminum blisters to smaller mono-polymer packs with an overwrap can cut the footprint by up to 70%. Yet fossil-based polypropylene, PET and polyethylene carry footprints similar to PVC. A switch justified on recyclability may therefore deliver little climate benefit, so leaders should ask which outcome a project is meant to achieve before approving it.

The FDA Filter: Why Sustainable Packaging Changes Move at Regulatory Speed

For an approved product, a primary packaging change is a regulated manufacturing change. Under 21 CFR 314.70, FDA assigns post-approval changes to reporting categories according to their potential to affect quality, from a prior-approval supplement down to an annual report. A material offering less protection than the original, or a new component in contact with a sensitive formulation, can bring stability studies, suitability testing and a longer review. Across many strengths, pack sizes and registrations, the effort can outweigh the benefit for an older, low-margin product.

This shapes where sustainable packaging takes hold first. Secondary packaging, inserts and shippers offer quicker returns because they do not touch the medicine, although printed content and serialization still need control. New products offer the cleanest opportunity, since packaging can be selected before stability programs and registration batches begin. Mature products call for selectivity, and comparability protocols may help where a family of similar changes can be planned in advance. Multinationals must also weigh Europe's new packaging regulation, which may pull material choices in directions US rules do not yet require.

Case Study: What One Injector Pen Take-Back Program Teaches US Manufacturers

Prefilled pens show the problem at scale. Each one combines plastic and glass in a single device. One global injectable manufacturer, producing around 600 million pens a year, began testing take-back in Denmark around 2020. Patients returned empty pens through pharmacies, and a waste handler crushed and separated them into clean material streams.

The results are encouraging in places and sobering in others. Danish return rates climbed from above 20% in early reporting to above 30% later, the company's best result anywhere, while other markets have not matched that uptake. The UK pilot began in November 2021 and went national in October 2022. By August 2023, about 200,000 pens had come back through a network of roughly 3,700 registered pharmacies, saving about two tonnes of plastic waste. Against global output in the hundreds of millions, those volumes remain small.

The second finding matters more for manufacturing strategy. Recovered material has gone into furniture and lamps, not new devices. The company's stated ambition is to return it to its own products, but strict quality requirements and purity problems have so far stood in the way. Meanwhile, it is developing a reusable pen in which the cartridge is replaced, a design response that addresses waste before it exists.

The company has also said that scale depends on rivals taking part, since industry-wide collection could raise volumes and financial stability. When it discussed the United States in 2022, it called the market a strong candidate but said the timing had to be right. Take-back can work, but patient behavior, infrastructure and competitor cooperation limit it, and end-of-life fixes cannot substitute for design decisions made years earlier.

Designing for the Next Decade: Making Sustainable Packaging a Development Gate

The most practical shift is one of timing. Many companies still choose packaging once a formulation is nearly settled, leaving few options open. Bringing packaging engineers, regulatory teams and procurement into early development lets a company weigh barrier need, line capability, patient usability, recyclability and state law exposure together. A stability-driven review may also show that some products need less protection than the format they inherited.

Capital planning should follow the same logic. A new blister line, device platform or contract packaging agreement can outlast several regulatory cycles, so equipment able to handle a range of materials may be worth a premium. Packaging data also needs a clear owner, because state reporting demands detailed material information.

Conclusion: Sustainable Packaging Is Now a Manufacturing Strategy

Sustainable packaging will not replace patient safety as the governing test in pharmaceutical manufacturing, and it should not. It has, however, become a real variable in decisions about materials, equipment, suppliers and launch timing. The US picture remains fragmented and contested, which argues for flexibility, not inaction. Companies that build packaging into early development and hold reliable data will be able to absorb whichever rules survive. They will also be able to show customers evidence instead of aspiration.

FAQ: Sustainable Pharmaceutical Packaging for US Executives

Are prescription drugs exempt from US packaging EPR laws?

Often in part, but not uniformly. Most state laws carve out some medical or federally regulated packaging, and the wording differs by state, so each product line needs its own legal review.

Does a recyclable blister need FDA review?

Usually some form of notification or approval applies for an approved product. The reporting category depends on the dosage form and on the change's potential to affect quality.

Is recyclable packaging always lower carbon?

No. Recyclability and climate impact are separate measures, and some fossil-based mono-materials have footprints close to PVC. Pack size and removal of aluminum can matter more.

Where should a drug manufacturer start?

Secondary packaging, inserts and shippers usually offer the fastest returns, with primary packaging addressed earliest in new product development.

Do take-back programs solve the device waste problem?

Not alone. Published pen programs show meaningful returns in some markets, but recovered plastic has not yet gone back into new devices, which keeps design and reuse central.